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reTo elucidate how the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor alirocumab modulates
lipoprotein(a) [Lp(a)] plasma levels, the authors performed a series of Lp(a) uptake studies in primary human
hepatocytes and dermal ﬁbroblasts and measured Lp(a) secretion from human hepatocytes. They found that
Lp(a) cellular uptake occurred in a low-density lipoprotein receptor–independent manner. Neither PCSK9 nor
alirocumab altered Lp(a) internalization. By contrast, the secretion of apolipoprotein (a) from human hepato-
cytes was sharply increased by PCSK9, an effect that was reversed by alirocumab. They propose that PCSK9
does not signiﬁcantly modulate Lp(a) catabolism, but rather enhances the secretion of Lp(a) from liver cells.
(J Am Coll Cardiol Basic Trans Science 2016;1:419–27) © 2016 The Authors. Published by Elsevier on behalf
of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).P roprotein convertase subtilisin kexintype 9 (PCSK9) inhibition with mono-clonal antibodies (mAbs), either as
monotherapy or in combination with statins,
recently emerged as a promising strategy to
lower circulating low-density lipoproteincholesterol (LDL-C) in patients with dyslipidemia and
cardiovascular disease risk (1–3). PCSK9 is a natural
circulating inhibitor of the low-density lipoprotein
receptor (LDLR). It binds to the LDLR, and after endo-
cytosis, targets the LDLR that would otherwise recycle
back to the cell surface for lysosomal degradation (4).
Both statins and anti-PCSK9 mAbs act by increasing
the abundance of LDLR at the surface of hepatocytes,
promoting an accelerated clearance of circulating
low-density lipoprotein (LDL) particles, thus lowering
LDL-C levels (4,5). But, unlike statins (6), anti-PCSK9
mAbs also promote an unexplained 25% to 30% reduc-
tion in circulating lipoprotein (a) [Lp(a)] levels (1,2,7).SEE PAGE 428There is strong epidemiological evidence that Lp(a)
is a highly atherogenic lipoprotein (8), because
elevated Lp(a) levels are independently and signiﬁ-
cantly associated with cardiovascular disease
(6,9,10). Lp(a) consists of a unique protein homolo-
gous to plasminogen, apolipoprotein (apo) (a)
[apo(a)], that is covalently tethered to the apolipo-
protein B100 [apoB100] moiety of an LDL particle
by a unique disulﬁde bond (11). Apo(a) is aoﬁ R&D and Regeneron, and by the Agence Nationale de la Re
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kDa), expressed exclusively by the liver, that contains
from 3 to more than 40 identical Kringle IV2 domains.
A strong inverse relationship exists between the
apo(a) isoform size and Lp(a) plasma concentration in
humans (12). Circulating Lp(a) concentrations appear
to be primarily controlled by synthesis rather than
catabolism (12). The molecular and cellular pathways
governing apo(a)/Lp(a) hepatic production and Lp(a)
cellular uptake and degradation are not well under-
stood (13). The potential role of the LDLR in Lp(a)
clearance remains controversial (8,14).
There is currently a clear need to understand how,
unlike statins, anti-PCSK9 mAbs reduce the circu-
lating levels of Lp(a) in patients. This could result from
an enhanced clearance and/or a reduced production of
Lp(a). To answer this question, we have investigated
the role of PCSK9 and of the LDLR in mediating Lp(a)
cellular uptake. We also investigated the effects of
PCSK9 and of the anti-PCSK9 monoclonal antibody
alirocumab on Lp(a) secretion from primary human
hepatocytes. We report that Lp(a) production from
hepatocytes is enhanced by PCSK9 and blunted by
alirocumab, whereas neither PCSK9 nor the LDLR
seem to signiﬁcantly modulate Lp(a) catabolism.
METHODS
FIBROBLASTS. Primary normal human dermal ﬁbro-
blasts were purchased from PromoCell (Heidelberg,
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421ﬁbroblasts were obtained either from the Corriel
Cell Repository (Camden, New Jersey) or isolated
from forearm biopsies of heterozygous or homozy-
gous familial hypercholesterolemic (FH) patients at
Groote Schuur Hospital (Cape Town, South Africa),
after obtaining written informed consent (5,15).
Dr. Jean-Pierre Rabès (University of Versailles
St-Quentin, France) genotype-checked each of the
HDF lines to ascertain its LDLR mutation status.
Fibroblasts were grown in DMEM (Thermo Fisher
Scientiﬁc, Saint-Aubin, France) containing 20% fetal
calf serum.
HEPATOCYTES. Human primary hepatocytes iso-
lated from 2 donors (BioreclamationIVT, Baltimore,
Maryland) were thawed in GRO-CP culture medium.
After 5 h, GRO-CP was replaced with GRO-HI cul-
ture medium (BioreclamationIVT). Hepatocytes were
seeded in 6 collagen-I–coated well plates with
increasing concentrations (0, 1.2, and 3.1 mg/ml) of
recombinant PCSK9 (Cyclex, Nagano, Japan) in the
absence or presence of saturating concentrations of
alirocumab (8 mg/ml) for 72 h, by replacing one-half of
the culture medium every day with fresh GRO-HI
medium, supplemented with or without PCSK9 and/
or alirocumab.
apoB100 AND APO(A) SECRETION FROM HEPATO-
CYTES. The culture medium was collected, spun to
get rid of cell debris, and assessed for apoB100 con-
centration with the EA 7001-1 sandwich enzyme-
linked immunosorbent assay (ELISA) kit (Assaypro,
St Charles, Missouri), and for apo(a) concentration
by ELISA with the EL3001-1 sandwich ELISA kit
(Assaypro) as well as by liquid chromatography-
tandem mass spectrometry (LC-MS/MS). Density KBr
gradient ultracentrifugation was performed on 72-h–
conditioned hepatocyte media to separately quantify
lipidated Lp(a) (density >1.21 g/ml) from lipid-free
apo(a) (density <1.21 g/ml) using apo(a) and apoB
ELISA kits. Apo(a) quantiﬁcations were performed by
LC-MS/MS (16); detailed methods of this assay can be
found in the Supplemental Appendix.
LDLR EXPRESSION. Hepatocytes were washed twice
with phosphate-buffered saline (PBS), and cellular
proteins were extracted in 100-ml cell lysis buffer
9803 (Cell Signaling Technology, Saint Quentin en
Yvelines, France) supplemented with complete mini-
protease inhibitor cocktail (Sigma-Aldrich, St. Louis,
Missouri). LDLR immunoblot analyses were per-
formed with a rabbit antihuman-LDLR polyclonal
antibody PAB8804 (Abnova, Walnut, California) on a
Sally Sue Simple Western device, using the 66-440
kDa separation master kit PS-MK12 (Protein Simple,
San Jose, California), and normalized to transferrinreceptor expression assessed using the AF2474
primary antibody (R&D Systems, Lille, France).
Lp(a) ISOLATION, PURIFICATION, AND LABELING.
Human plasma from 6 anonymous donors with Lp(a)
levels above 30 mg/dl was purchased from Bio-
reclamationIVT. We determined by LC-MS/MS their
mean number of Kringle IV2 domains to be 9.8, 9.9,
11.6, 12.1, 17.5, and 19.1. Lp(a) was isolated by
sequential ultracentrifugation (1.050 < d <1.125 g/ml)
at 40,000 g. Lp(a) fraction was dialyzed against PBS
(137 mmol/l NaCl, 2.7 mmol/l KCl 8 mmol/l Na2HPO4,
and 2 mmol/l KH2PO4) and puriﬁed by fast perfor-
mance liquid chromatography on a lysine sepharose
4B column (GE Healthcare, Velizy-Villacoublay,
France). Lp(a) was subsequently dialyzed against
PBS, ﬂuorescently labeled with boron dipyrrome-
thene (BODIPY) (Thermo Fisher Scientiﬁc), and puri-
ﬁed by gel ﬁltration on Sephadex G-25 columns
(NAP-5, Sephadex G25 0.5 ml, GE Healthcare).
The absence of free label was checked by high-
performance liquid chromatography on BioSec5 col-
umns (Agilent Technologies, Santa Clara, California).
The structural integrity of Lp(a) was veriﬁed by
electrophoresis migration on buffered agarose
hydrogels (pH 8.5) using the Hydrasis electrophoresis
system (Sebia, Norcross, Georgia) and Sudan Black
staining (Supplemental Figure 1). Lp(a), either
reduced with 50 mmol/l dithiothreitol or not reduced,
was subjected to sodium dodecyl sulfate poly-
acrylamide gel electrophoresis on 4% to 12% Tris-
Glycine gels (Thermo Fisher Scientiﬁc); transferred
onto nitrocellulose membrane; and immunoblotted
with a rabbit monoclonal anti-human apo(a) anti-
body, clone EPR6474, and an antirabbit immuno-
globulin G horseradish peroxidase secondary
antibody (OriGene, Rockville, Maryland). Immunore-
active bands were visualized with Amersham ECL
western blotting detection reagent (GE Healthcare).
FLUORESCENT LDL AND Lp(a) UPTAKE IN FIBROBLASTS.
Control and FH ﬁbroblasts were seeded in ﬂat-
bottomed, 96-well plates (35,000 cells/well) in
DMEM containing 0.5% fetal calf serum for 24 h at
37C and were subsequently supplemented with
10 mg/ml mevastatin (Sigma-Aldrich) for 24 h. The
medium was replaced with fresh medium containing
10 mg/ml mevastatin with or without recombinant
gain-of-function PCSK9 (600 ng/ml) (Cyclex) with
or without saturating concentrations of alirocumab
(19.2 mg/ml) for 5 h at 37C (5,15). LDL-BODIPY (Life
Technologies, Saint Aubin, France) or Lp(a)-BODIPY
(10 mg/ml ﬁnal concentration) were added to the cul-
ture medium for the ﬁnal 3 h of the incubation time.
In a subset of experiments, an excess of unlabeled
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addition of ﬂuorescent lipoproteins. Fibroblasts were
washed gently with PBS, lifted with Accutase (Sigma-
Aldrich), and resuspended in ice-cold PBS containing
1% bovine serum albumin (BSA). Cells were then
washed twice in ice-cold PBS with 1% BSA and once in
ice-cold PBS before ﬁxation with PBS containing 0.5%
paraformaldehyde (Sigma-Aldrich). Finally, cells
were resuspended in PBS supplemented with 0.2%
trypan blue to quench cell-surface bound ﬂuorescent
LDL or Lp(a) prior to ﬂow cytometry analysis (17).
Cells were analyzed using an LSRII cytometer (Beck-
ton Dickinson, Le Pont de Claix, France) and the
FlowJo software (Tree Star, Ashland, Oregon) of the
Cellular and Tissular Imaging Core Facility of Nantes
University (MicroPICell). The mean ﬂuorescence
intensity of cells incubated without ﬂuorescent lipo-
proteins was subtracted from the mean ﬂuorescence
intensity of cells incubated with ﬂuorescent lipopro-
teins to determine the speciﬁc mean ﬂuorescence
intensity level of lipoprotein uptake, expressed in
arbitrary units (5,15). In a subset of experiments,
control and LDLR defective homozygote (Ho) FH ﬁ-
broblasts were seeded in poly-L-lysine–coated 8-well
Millicell EZ slides (Merck-Millipore, Fontenay Sous
Bois, France) (15,000 cells/well). Cells were treated as
described in the previous text. LDL-BODIPY or Lp(a)-
BODIPY (20 mg/ml) was added to the medium for the
ﬁnal 4 h of the incubation. Cells were washed twice in
ice-cold PBS with 1% BSA, rinsed twice in ice-cold
PBS, ﬁxed in PBS containing 4% paraformaldehyde
for 15 min at room temperature, and then rinsed twice
in PBS. Slides were mounted with cover slides in
Prolong antifade reagent containing DAPI (Life
Technologies) and visualized on a confocal A1 N-SIM
microscope (Nikon, Melville, New York).
LDL AND Lp(a) CELLULAR UPTAKE IN HEPATOCYTES.
Human primary hepatocytes were seeded in ﬂat-
bottom 96-well collagen-I–coated plates (50,000
cells/well) in GRO-CP culture medium for 5 h at 37C
and then grown overnight in serum-free GRO-HI me-
dium. Hepatocytes were then treated with or without
recombinant wild-type PCSK9 (3.1 mg/ml) for 24 h. LDL
and Lp(a) uptake experiments were conducted for 5 h,
as described in the previous text for primary ﬁbro-
blasts, in the presence or absence of recombinant wild-
type PCSK9 (0, 1.2, and 3.1 mg/ml), with or without an
LDLR-blocking antibody (500 mg/ml) or immunoglob-
ulin G isotype control (clones 472,413 and 11,711,
respectively, R&D Systems) and/or saturating con-
centrations (8 mg/ml) of alirocumab. Supernatants
were harvested for Lp(a) integrity assessment
by western blot under reducing and nonreducingconditions, as described in the previous text, and cells
were washed twice with PBS before ﬂuorescence
measurement on a Tecan spectroﬂuorometer (Tecan,
Männedorf, Switzerland). In a subset of experiments,
hepatocyteswerewashed intensively (i.e., 3with PBS
with 0.8% BSA, twice with PBS with 0.8% BSA sup-
plemented with 0.2 mol/l epsilon aminocaproic acid,
and twice with 0.2 mol/l acetic acid/0.5 mol/l NaCl
solution [pH 2.5]), as previously described (14), before
ﬂuorescence measurements. Cellular proteins were
collected in cell lysis buffer 9803 (Cell Signaling
Technology) supplemented with cOmplete Mini pro-
tease inhibitor cocktail and intracellular apo(a) con-
tents assessed by ELISA, as in the previous text.
STATISTICAL ANALYSES. Analyses were performed
using SAS version 9.2 for Windows 7 (SAS Institute,
Cary, North Carolina). Data are presented as mean 
SEM. Comparisons between groups were made using
1- and 2-way analysis of variance with Newman-Keuls
post hoc tests. All p values <0.05 are considered
statistically signiﬁcant.
RESULTS
THE LDLR DOES NOT PROMOTE Lp(a) CELLULAR
UPTAKE EX VIVO. The role of the LDLR on Lp(a)
cellular uptake was ﬁrst investigated in primary
ﬁbroblasts isolated from 1 wild-type control, 1 hetero-
zygous (He) FH, 7 LDLR-defective HoFH, and 4 LDLR-
negative HoFH patients (Supplemental Table 1)
treated with mevastatin with or without PCSK9 in the
presence or absence of alirocumab. We veriﬁed that
LDL cellular uptake correlated with LDLR cell surface
expression levels (5,15). Maximal ﬂuorescent LDL
internalization was observed in control ﬁbroblasts,
followed by HeFH ﬁbroblasts, and then receptor-
defective and receptor-negative HoFH ﬁbroblasts
(Figure 1A). PCSK9 reduced whereas alirocumab re-
stored LDL uptake in all ﬁbroblast lines, except for
those receptor-negative HoFH ﬁbroblasts totally lack-
ing LDLR function (Figures 1A and 1B). Fluorescent LDL
uptake was reduced by the addition of 20-fold excess
unlabeled LDL to the culture medium (Figure 1C). By
contrast, Lp(a) uptakewas similar in allﬁbroblast lines,
irrespective of the LDLR mutation status or LDLR
expression level. Neither PCSK9 nor alirocumab
signiﬁcantly altered the ability of any tested ﬁbroblast
line to internalize ﬂuorescent Lp(a) (Figures 1D and 1E).
Fluorescent Lp(a) uptake was reduced similarly by the
addition of 20-fold excess unlabeled Lp(a) into the
culture medium in control and FH ﬁbroblasts
(Figure 1F). These data demonstrate that Lp(a) cellular
uptake is not dependent on the presence of a func-
tional LDLR.
FIGURE 1 Lp(a) Uptake Is Not Modulated by LDLR Expression in Human Fibroblasts
Flow cytometric assessment of ﬂuorescent low-density lipoprotein (LDL) (A) and ﬂuorescent lipoprotein(a) [Lp(a)] (D) uptake in dermal skin ﬁbroblast isolated from 1
non–familial hypercholesterolemia (FH) (control), 1 heterozygous (He) FH, 7 receptor-defective homozygous (Ho) FH, and 4 receptor-negative HoFH patients. Cells
were treated with mevastatin with or without recombinant gain-of-function proprotein convertase subtilisin kexin type 9 (PCSK9) (600 ng/ml) and/or alirocumab
(19.2 mg/ml). Representative confocal microscopy images (Z stacks) of ﬂuorescent LDL (red hot) (B) and ﬂuorescent Lp(a) (yellow hot) (E) cellular uptake in control and
HoFH ﬁbroblasts are displayed. Nuclei are shown in blue. Relative uptake of ﬂuorescent LDL (C) and ﬂuorescent Lp(a) (F) in the presence of 20-fold excess unlabeled
LDL and Lp(a), respectively, in ﬁbroblasts from 1 non-FH control and 3 HoFH patients. DMFI is the mean ﬂuorescence intensity difference between cells incubated
with and cells incubated without ﬂuorescent lipoproteins (i.e., autoﬂuorescence). DMFI is in arbitrary units. *p < 0.001, **p < 0.03 vs. non-FH control without PCSK9
and without LDL excess, #p < 0.005 vs. non-FH control without PCSK9 and without alirocumab, using 2-way analysis of variance on rank-transformed values with
post-hoc Newman-Keuls test. Histograms represent the mean  SEM of a minimum of 3 independent experiments (except for HeFH, n ¼ 1).
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423PCSK9 INHIBITS LDL, BUT NOT Lp(a), CELLULAR
UPTAKE BY HUMAN PRIMARY HEPATOCYTES. To
elucidate whether PCSK9 alters Lp(a) hepatic clear-
ance, primary human hepatocytes isolated from 2
donors were treated with increasing concentrations
of PCSK9 in the absence or presence of saturating
concentrations of alirocumab. Cellular LDLR expres-
sion assessed by Western blot was reduced in a dose-
dependent manner in hepatocytes treated with
increasing doses of PCSK9, an effect that was abol-
ished by alirocumab (Figure 2). LDL cellular uptake by
primary human hepatocytes correlated with LDLR
expression levels and was reduced in cells treated
with PCSK9. This effect of PCSK9 on LDL cellular
uptake was reversed by alirocumab (Figure 3A). We
veriﬁed the functionality of the LDLR in primary hu-
man hepatocytes by adding an antibody targeting the
extracellular domain of the LDLR to the culture me-
dium. Blocking the LDLR with this antibody reduced
the cellular uptake of ﬂuorescent LDL (Figure 3A).By contrast, PCSK9, alirocumab, and the antibody
targeting the extracellular domain of the LDLR did not
signiﬁcantly alter the cellular uptake of ﬂuorescent
Lp(a) in human primary hepatocytes (Figure 3B). The
inability of PCSK9 to modulate Lp(a) cellular uptake
was observed across a broad range of Lp(a) concen-
trations (Supplemental Figure 2). To demonstrate that
primary hepatocytes effectively promote cellular
endocytosis of both LDL and Lp(a), cells were washed
with a highly stringent buffer to eliminate any LDL and
Lp(a) particles that were bound to the cell surface.
After stringent washing, PCSK9 reduced ﬂuorescent
LDL endocytosis but had no effect on ﬂuorescent Lp(a)
endocytosis (Supplemental Figure 3). We conﬁrmed
that native Lp(a) (i.e., unlabeled) and ﬂuorescently
labeled Lp(a) were equally internalized by primary
hepatocytes by measuring intracellular apo(a) con-
tents. Furthermore, we demonstrated that PCSK9 had
no effect on native Lp(a) uptake by primary hepato-
cytes (Supplemental Figure 4). The integrity of Lp(a)
FIGURE 2 PCSK9 Reduces LDLR Expression in Human
Primary Hepatocytes: An Effect Blocked by Alirocumab
Low-density lipoprotein receptor (LDLR) expression was
measured in hepatocytes, treated for 72 h with increasing con-
centrations of recombinant PCSK9 with or without saturating
concentrations (8 mg/ml) of alirocumab, by simple western blot.
LDLR levels were normalized to transferrin receptor expression.
Histograms represent the mean  SEM of 3 independent ex-
periments. *p < 0.01 vs. control (no PCSK9); **p < 0.05 vs.
same dose of PCSK9 without alirocumab, using 1-way analysis of
variance on rank-transformed values with post-hoc Newman-
Keuls test. A representative simple Western image is displayed.
Abbreviations as in Figure 1.
FIGURE 3 Inhibiting LDLR Expression With PCSK9 or LDLR
Function With a Blocking Antibody Does Not Affect Lp(a)
Uptake by Human Primary Hepatocytes
Cells were treated with recombinant PCSK9 ( alirocumab) or an
anti-LDLR blocking antibody (Ab). An isotype control antibody
was used as control (Ctrl). Fluorescent LDL (A) and ﬂuorescent
Lp(a) (B) cellular uptake was measured. *p < 0.001 vs. control
(black bars). **p < 0.001 vs. PCSK9 treatment (white bars).
***p < 0.001 vs. anti-LDLR blocking antibody (light gray bars),
using 1-way analysis of variance analysis on rank-transformed
values with post-hoc Newman-Keuls test. Histograms represent
the mean  SEM of 7 independent experiments from 2 hepato-
cyte donors. Abbreviations as in Figures 1 and 2.
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424particles, in particular the covalent tethering of apo(a)
to apoB100 during the cellular incubation process, was
veriﬁed by immunoblot analysis under denaturing and
nondenaturing conditions (Supplemental Figure 5).
Taken together, these data demonstrate that PCSK9
does not modulate Lp(a) cellular uptake in human
hepatocytes.
PCSK9 ENHANCES apo(a)/Lp(a) CELLULAR SECRETION
BY HUMAN PRIMARY HEPATOCYTES. To elucidate the
potential role of PCSK9 in modulating Lp(a) secretion,
we used primary human hepatocytes isolated from 2
donors and grown in the absence of serum lipopro-
teins. Cells were incubated with increasing concen-
trations of PCSK9 in the absence or presence of
saturating concentrations of alirocumab. The
amounts of human apoB100 and apo(a) in the culture
medium were quantiﬁed by ELISA and/or LC-MS/MS.
Both lipid-free and lipidated apoB and apo(a) weredetected in the culture medium of human primary
hepatocytes, indicating that these cells produce
and secrete apoB-containing lipoproteins (LpB) as
well as Lp(a). The addition of PCSK9 increased the
concentration of apoB in the culture medium by
2-fold and apo(a) in the culture medium by up to
3-fold; both effects were reversed by alirocumab
(Figures 4A and 4B). The effects of PCSK9 were similar
in hepatocytes isolated from both donors.
DISCUSSION
In thiswork,we investigated themechanisms bywhich
anti-PCSK9 mAbs reduce circulating Lp(a) levels in
humans. We showed that Lp(a) cellular uptake was not
FIGURE 4 PCSK9 Treatment Increases Apo(a) Secretion
From Primary Human Hepatocytes: An Effect Blocked by
Alirocumab
Cells were treated with increasing concentrations of recombinant
PCSK9 with or without alirocumab for 72 h. ApoB100 (A) and
apo(a) (B) were quantiﬁed in the culture medium by enzyme-
linked immunosorbent assay and liquid chromatography-tandem
mass spectrometry, respectively. *p < 0.05 vs. control
(no PCSK9). **p < 0.05 vs. same dose of PCSK9 without alir-
ocumab, using 1-way analysis of variance on rank-transformed
values with post-hoc Newman-Keuls test. Histograms represent
the mean  SEM of 3 independent experiments from 2 hepato-
cyte donors. Abbreviations as in Figure 1.
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425modulated by the LDLR or by PCSK9 ex vivo. Further-
more, we demonstrated that PCSK9 enhanced Lp(a)
production from primary hepatocytes, an effect that
was blunted by alirocumab.
The physiological role of the LDLR in mediating
Lp(a) plasma clearance is controversial. We used a
well-characterized collection of dermal ﬁbroblasts
(from non-FH, HeFH, and HoFH patients) (5), to
show that Lp(a) cellular uptake occurs to a similar
extent whether the expression and function of the
LDLR is maximal, abrogated genetically, or reduced
by PCSK9. The functionality of the LDLR was
conﬁrmed by performing LDL uptake experiments in
parallel (5). In line with our results, Reblin et al. (18)
showed that the speciﬁc uptake of I125-Lp(a) (but not
that of I125-LDL) was similar in wild-type and LDLR-
knockout mouse embryonic ﬁbroblasts. Furthermore,Niemeier et al. (19) found that Lp(a) was a very weak
ligand for the LDLR in BIAcore studies. Our results
are also in agreement with clinical studies showing
that PCSK9 inhibition (with evolocumab) promoted
signiﬁcant reductions in both circulating LDL-C
(24%) and Lp(a) (19%) in 6 receptor-defective
HoFH patients and reduced Lp(a) (18%), but not
LDL-C (þ15%) levels in 2 receptor-negative HoFH
patients (20). Finally, our results are concordant with
the previously published observations that up-
regulating LDLR expression even with the most
potent statins does not reduce Lp(a) in humans (6),
and that Lp(a) plasma clearance occurs at similar
catabolic rates in non-FH, HeFH, and HoFH
patients (12,21).
In this study, we also performed Lp(a) and LDL
uptake experiments in primary hepatocytes obtained
from 2 donors. In line with our ﬁndings in ﬁbroblasts,
we showed that PCSK9 reduces LDLR expression and
function (i.e., LDL uptake) without altering Lp(a)
cellular uptake. Blocking LDLR function with an
antibody yielded similar results. In contrast to our
ﬁndings, a recent study found that PCSK9 reduced the
internalization of Lp(a) in HepG2 cells (14). We are
uncertain how to explain the discrepancies between
the 2 studies. One possible explanation would be that
we used primary human hepatocytes, whereas
Romagnuolo et al. (14) used a hepatoma cell line.
However, Romagnuolo et al. (14) found that PCSK9
reduced the uptake of Lp(a) in human dermal ﬁbro-
blasts expressing the LDLR. Because Romagnuolo
et al. (14) observed that recombinant apo(a) uptake,
unlike Lp(a) particle uptake, was not altered by PCSK9
and/or LDLR expression in dermal ﬁbroblasts, we
conﬁrmed in the present study that apo(a) had not
detached from Lp(a) particles during our incubation
process (Supplemental Figure 5). A less likely expla-
nation for the discrepancies between the 2 studies is
that there were differences in apo(a) isoforms, as we
used Lp(a) with apo(a) isoforms containing 9 to 19
Kringle IV2 domains, whereas Romagnuolo et al. (14)
used apo(a) isoforms containing 7 to 8 Kringle IV2
domains (14). A third possible explanation for the
discrepancies between the 2 studies is that we used
PCSK9 concentrations (600 ng/ml of gain-of-function
PCSK9 and 1.2 to 3.1 mg/ml of wild-type PCSK9)
closer to the physiological range than those used by
Romagnuolo et al. (14) (10 to 20 mg/ml).
Because we did not observe any effect of PCSK9
on Lp(a) cellular uptake by human hepatocytes, we
tested whether PCSK9 might modulate Lp(a) secre-
tion from these cells. We showed a PCSK9 dose-
dependent increase in both apoB and apo(a) (free
and lipidated) in the culture medium, an effect that
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Sta-
tins reduce LDL-C levels by increasing the expression
of the LDL receptor. Monoclonal antibodies targeting
PCSK9, a new class of lipid-lowering drugs, also
reduce LDL-C levels by decreasing the degradation of
the LDL receptor. We now report a cellular mechanism
indicating that PCSK9 enhances the hepatic produc-
tion of Lp(a), a highly atherogenic lipoprotein sub-
class. These results underline why unlike statins,
monoclonal antibodies targeting PCSK9 also reduce
circulating Lp(a) in dyslipidemic patients.
TRANSLATIONAL OUTLOOK: Our results pave
the way for in vivo turnover studies of major Lp(a)
apolipoprotein components [apo(a) and apoB100]
in patients with elevated Lp(a) plasma levels. The
exact molecular and cellular mechanisms governing
the secretion and assembly of Lp(a) and its modu-
lation by PCSK9 remain to be fully elucidated.
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426was blunted by alirocumab. Because PCSK9 reduces
LDLR expression, the variations in apoB levels
observed in the medium of primary hepatocytes
treated with PCSK9 and/or alirocumab cannot be
attributed to an increased production of LpB, but
must rather be a consequence of reduced clearance
of newly secreted LpB, as the LDLR simultaneously
promotes apoB uptake. By contrast, we found that
PCSK9 and alirocumab did not modulate Lp(a) up-
take in primary hepatocytes. The increase in apo(a)
levels measured in the medium of human hepato-
cytes treated with PCSK9 therefore indicates that
PCSK9 enhances the production/secretion of Lp(a)
by those cells, an effect that is abolished by alir-
ocumab. The molecular mechanisms by which PCSK9
enhances apo(a) secretion and Lp(a) assembly (i.e.,
disulﬁde bond formation between apo(a) and
apoB100 on LDL particles), which likely occurs at
the surface of hepatocytes (7), certainly merits
further investigation. In that respect, another class
of lipid-lowering drugs, the CETP inhibitors, which
do not act on the LDLR, but rather on the lipid
content of LDL particles, also signiﬁcantly reduces
Lp(a) levels. It is farfetched to speculate that PCSK9,
which is known to associate with LDL particles in
the plasma (22,23), might enhance the conformation/
ability of LDL particles to serve as substrates for
Lp(a) formation.
CONCLUSIONS
Therefore, we propose that physiological concentra-
tions of PCSK9 do not signiﬁcantly modulate Lp(a)
catabolism, but rather enhance the generation of Lp(a),
and that anti-PCSK9 mAbs reduce Lp(a) levels pri-
marily by altering this pathway. This hypothesis couldbe evaluated by performing a series of Lp(a) turnover
studies in patients before and after treatment with
monoclonal antibodies targeting PCSK9.
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